Both Remicade and Humira have equal effictiveness ... monoclonal antibody that works by blocking tumor necrosis factor alpha (TNF-alpha). The side effects are usually mild, but serious side ...

Usually managed with steroids and antihistamine, occasionally requiring a change of anti-TNF agent. Infliximab is associated with infusion reactions (approximately 10% - usually mild). 1,2 ...

Data presentations including the extended LIBERTY studies to highlight the long-term treatment goals of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab The data underscores ...

TNF-α is a potent inducer of the inflammatory response, a key regulator of innate immunity and plays an important role in the regulation of Th1 immune responses against intracellular bacteria and ...

Among patients who were initiated on the tumor necrosis factor (TNF) inhibitor infliximab (Remicade), 55.3% of those receiving molecular medicine-informed guidance with insights from a real-time ...

Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36 , 1681–1690 (1993). Article CAS Google Scholar ...

Infliximab is an intravenous (IV) anti-TNF-α therapy, in which its safety and efficacy is supported by nearly 20 years of real-world experience. Whilst infliximab is proven to be effective in ...

Background. A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform ...

Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA ® (infliximab-dyyb) Findings reinforce clinical decision-making in long-term management ...